What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Pentose Phosphate Pathway: Steps and Functions

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-19

The pentose phosphate pathway is a cytosolic route of glucose metabolism that produces NADPH and ribose-5-phosphate instead of ATP. It runs in two phases: an oxidative phase that commits glucose-6-phosphate to two molecules of NADPH plus one molecule of ribose-5-phosphate, and a non-oxidative phase that shuffles carbon skeletons to match cellular demand.

This pathway matters because it supplies the reducing power for biosynthesis and antioxidant defense and the sugar backbone for nucleotides. It is the reason red blood cells can survive oxidative stress, the reason favism exists, and one of the most frequently activated metabolic nodes in proliferating cells.

What Is the Pentose Phosphate Pathway?

The pentose phosphate pathway (PPP), also called the phosphogluconate pathway or hexose monophosphate shunt, is a set of cytosolic reactions that oxidize glucose-6-phosphate and rearrange phosphorylated sugars. It does not consume oxygen and does not generate ATP. Its currency is NADPH and phosphorylated pentoses.

The pathway is sometimes written as "phosphate pentose pathway," a word-order variant that appears in older texts and translated materials. The correct term is pentose phosphate pathway, because the sugars involved are pentose phosphates.

Why It Matters

Every cell needs reducing equivalents for anabolic reactions. Fatty acid synthesis, cholesterol synthesis, nucleotide synthesis, and the regeneration of reduced glutathione all consume NADPH. The PPP is the principal cytosolic source of that NADPH. In tissues with high biosynthetic demand, such as liver, adipose tissue, adrenal cortex, and lactating mammary gland, the pathway is highly active. In red blood cells, which have no mitochondria and no other NADPH source, the PPP is the sole defense against oxidative damage.

Summary Table

Feature	Oxidative phase	Non-oxidative phase
Direction	Irreversible	Reversible
Net output	2 NADPH, 1 ribose-5-phosphate per glucose-6-phosphate	Interconverts 5-carbon and 6-carbon sugars
Key enzyme	Glucose-6-phosphate dehydrogenase (G6PD)	Transketolase and transaldolase
Cofactor	NADP+	Thiamine pyrophosphate (transketolase)
Regulation	Inhibited by high NADPH/NADP+ ratio	Driven by substrate availability
Location	Cytosol	Cytosol
Main purpose	Reducing power and pentose sugar	Carbon recycling and sugar rebalancing

The Oxidative Phase

The oxidative phase is the committed, irreversible arm of the pathway. It converts glucose-6-phosphate into ribulose-5-phosphate and releases two molecules of NADPH.

Step 1: Glucose-6-phosphate dehydrogenase

Glucose-6-phosphate dehydrogenase (G6PD) oxidizes glucose-6-phosphate to 6-phosphogluconolactone, reducing NADP+ to NADPH. This is the rate-limiting step and the single most regulated point in the pathway. G6PD is the enzyme missing or defective in the most common inherited enzyme disorder of red blood cells, and it is the major enzyme of the pathway as described in clinical case literature [1].

Step 2: 6-phosphogluconolactonase

6-phosphogluconolactonase hydrolyzes the lactone ring of 6-phosphogluconolactone to give 6-phosphogluconate. This is a straightforward hydrolysis with no redox chemistry.

Step 3: 6-phosphogluconate dehydrogenase

6-phosphogluconate dehydrogenase oxidatively decarboxylates 6-phosphogluconate. The products are ribulose-5-phosphate, a second molecule of NADPH, and one molecule of CO2. The carbon lost here is C1 of the original glucose.

Step 4: Phosphopentose isomerase

Ribulose-5-phosphate is converted to ribose-5-phosphate by phosphopentose isomerase. Ribose-5-phosphate is the sugar used directly in nucleotide biosynthesis, feeding into 5-phosphoribosyl-1-pyrophosphate (PRPP) and then into purines and pyrimidines.

At this point the oxidative phase has delivered the two headline products: two NADPH and one ribose-5-phosphate per glucose-6-phosphate consumed.

The Non-oxidative Phase

The non-oxidative phase is a reversible set of carbon-shuffling reactions. It lets the cell run the pathway in different modes depending on whether it needs NADPH, ribose-5-phosphate, or both.

Step 5: Ribulose-5-phosphate epimerase

Ribulose-5-phosphate epimerase converts ribulose-5-phosphate to xylulose-5-phosphate. The cell now has two pentose phosphates available: ribose-5-phosphate and xylulose-5-phosphate.

Step 6: Transketolase

Transketolase transfers a two-carbon unit from xylulose-5-phosphate to ribose-5-phosphate, producing glyceraldehyde-3-phosphate and sedoheptulose-7-phosphate. Transketolase requires thiamine pyrophosphate (TPP, derived from vitamin B1) as a cofactor. This is why thiamine status affects flux through the non-oxidative arm.

Step 7: Transaldolase

Transaldolase transfers a three-carbon unit from sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate, producing erythrose-4-phosphate and fructose-6-phosphate.

Step 8: Second transketolase reaction

A second transketolase reaction transfers a two-carbon unit from another xylulose-5-phosphate to erythrose-4-phosphate, producing fructose-6-phosphate and glyceraldehyde-3-phosphate.

The net effect of the non-oxidative phase is to convert three molecules of ribulose-5-phosphate into two molecules of fructose-6-phosphate and one molecule of glyceraldehyde-3-phosphate. Both of these are glycolytic intermediates, so the pathway can recycle its carbon back into glycolysis when NADPH demand is high and ribose demand is low.

The Four Metabolic Modes

Textbooks describe four operating modes based on what the cell needs:

Need NADPH and ribose-5-phosphate equally. The oxidative phase runs, and its ribose-5-phosphate output is used directly.
Need NADPH more than ribose-5-phosphate. The oxidative phase runs, and the non-oxidative phase recycles pentoses back into glycolytic intermediates, which re-enter the pathway as glucose-6-phosphate.
Need ribose-5-phosphate more than NADPH. Glycolytic intermediates feed into the non-oxidative phase without running the oxidative phase, sparing NADPH.
Need both at high rates. Glycolysis feeds carbon into the non-oxidative phase, which produces ribose-5-phosphate while the oxidative phase generates NADPH.

Pathway Overview

The following flowchart traces the main decision path from glucose-6-phosphate to the two product branches.

flowchart TD
    A[Glucose 6 phosphate] --> B[G6PD]
    B --> C[6 phosphogluconolactone]
    C --> D[6 phosphogluconate]
    D --> E[6 phosphogluconate dehydrogenase]
    E --> F[Ribulose 5 phosphate]
    F --> G[NADPH output]
    F --> H[Ribose 5 phosphate]
    F --> I[Xylulose 5 phosphate]
    I --> J[Transketolase]
    H --> J
    J --> K[Transaldolase]
    K --> L[Fructose 6 phosphate and Glyceraldehyde 3 phosphate]

Functions of the Pathway

NADPH for Reductive Biosynthesis

NADPH is the electron donor for reductive biosynthesis. Fatty acid synthase, HMG-CoA reductase (the cholesterol pathway), and the de novo synthesis of many amino acids all consume NADPH. Cells that make lipids at high rates, such as hepatocytes and adipocytes, run the PPP heavily to keep up with demand.

NADPH for Glutathione Recycling

Glutathione peroxidase reduces hydrogen peroxide to water using reduced glutathione (GSH), converting GSH to its oxidized dimer (GSSG). Glutathione reductase then regenerates GSH, and it requires NADPH. Without a steady NADPH supply, the GSH pool collapses, peroxide accumulates, and proteins and lipids are damaged. Red blood cells depend entirely on this loop because they lack mitochondria and cannot make NADPH any other way.

Ribose-5-phosphate for Nucleotide Synthesis

Ribose-5-phosphate is the sugar that becomes the backbone of RNA and DNA. It is converted to PRPP by ribose-phosphate pyrophosphokinase, and PRPP is the activated sugar used in purine and pyrimidine nucleotide synthesis. Dividing cells need large amounts of ribose-5-phosphate, which is why the PPP is upregulated in many cancers.

Carbon Recycling

The non-oxidative arm lets the cell recover pentoses that are not needed for nucleotide synthesis. Instead of wasting them, it converts them back into glycolytic intermediates. This flexibility is what makes the PPP a shunt rather than a dead-end branch.

Regulation

The pathway is regulated primarily by the availability of its substrates and the NADPH/NADP+ ratio. G6PD is strongly inhibited by a high NADPH/NADP+ ratio, which means that when the cell already has plenty of reducing power, the oxidative phase slows down. When NADPH is consumed by biosynthesis or antioxidant reactions, the ratio falls, and G6PD activity rises.

This is a feedback loop rather than a hormonal switch. Insulin and other growth signals can increase expression of G6PD and other pathway enzymes over longer timescales, but the fast control is the redox ratio itself. Because the pathway runs in the cytosol, it is spatially separate from mitochondrial NADPH production via the malic enzyme and isocitrate dehydrogenase, and the two pools are not fully interchangeable.

How the Pathway Is Studied

Researchers measure PPP flux using several approaches:

NADPH/NADP+ ratio assays. These report the redox state that controls G6PD activity.
G6PD activity assays. Spectrophotometric assays follow NADPH production at 340 nm in red cell lysates or tissue homogenates.
Isotopic tracing. Carbon-13 or carbon-14 labeled glucose at specific positions reveals how much carbon flows through the oxidative versus non-oxidative arm.
Enzyme expression profiling. Transcript and protein levels of G6PD, transketolase, and transaldolase indicate pathway capacity.

In clinical laboratories, G6PD activity is measured on dried blood spots or fresh red cells. Neonatal screening programs use fluorescence spot tests or quantitative assays, and abnormal results are confirmed by genetic testing [2]. The choice of screening strategy affects detection yield, and universal versus targeted screening remains an active question [3].

Clinical Relevance: G6PD Deficiency

G6PD deficiency is the most common inherited enzyme disorder of red blood cells worldwide, affecting an estimated 500 million people [2]. It is X-linked, so males are affected more often and more severely than females [4].

Mechanism of Hemolysis

Red blood cells cannot make new enzymes. When G6PD activity is low, the cell cannot regenerate NADPH fast enough during oxidative stress. GSH falls, peroxide rises, hemoglobin is oxidized and precipitates as Heinz bodies, and the membrane is damaged. The result is acute hemolytic anemia, with fatigue, jaundice, dark urine, and a fall in hemoglobin. Laboratory findings include elevated lactate dehydrogenase, indirect hyperbilirubinemia, and low haptoglobin [5].

Triggers

Classic triggers include fava beans, certain antimalarials, sulfonamides, dapsone, and some quinolones [5][6][7]. Infection, metabolic stress, and surgery can also precipitate hemolysis [1]. A case report of a 70-year-old man shows that the diagnosis can be missed for decades when no trigger has been encountered [8]. A separate case in a 16-year-old with recurrent perianal abscess and fistula raises the possibility that G6PD dysfunction affects immune defense and epithelial repair beyond the red cell [9].

Favism

Fava bean ingestion is the classic trigger, and the term favism comes directly from this association. In Sardinia, where G6PD deficiency prevalence is high, public awareness of fava beans as a trigger is nearly universal, though misconceptions persist about pollen and pea consumption [10]. A recent case describes a patient presenting with profound acute hemolytic anemia requiring transfusion after eating fava bean-containing snacks [5].

Medication and Surgical Considerations

Drug avoidance lists still caution against quinolones in G6PD deficiency, though a large cohort study found the adjusted odds ratio for hemolysis-related outcomes was 1.29 with a confidence interval that crossed 1.0, meaning the evidence for a strong quinolone effect is limited [6]. Dapsone can cause hemolysis and a fall in oxygen saturation even in patients with normal G6PD levels, so the drug itself carries risk independent of genotype [7]. In surgery, perfusion and anesthesia teams modify oxygen tension, avoid oxidant drugs such as methylene blue, and minimize mechanical hemolysis [11][12].

Thiamine and Transketolase

Transketolase requires thiamine pyrophosphate. Severe thiamine deficiency therefore impairs the non-oxidative phase, which can limit the cell's ability to rebalance sugars and produce ribose-5-phosphate. This is one reason thiamine status matters in conditions with high PPP demand, such as rapid cell proliferation and recovery from oxidative stress.

The Pathway in Disease and Cancer

The PPP is frequently upregulated in cancer. Chronic stress has been shown to activate an RNMT-ADRB2-MYCBP-PPP axis in esophageal squamous cell carcinoma, increasing expression of G6PD and transketolase and promoting malignant progression [13]. In asthma, airway smooth muscle cells show reduced G6PD expression and a low GSH/GSSG ratio, linking the pathway to airway dysfunction [14]. These findings place the PPP at the intersection of metabolism, redox signaling, and cell fate.

Common Mistakes and Limitations

Confusing NADPH with NADH. NADPH is used for reductive biosynthesis and antioxidant defense. NADH is used mainly for ATP production in the electron transport chain. They are not interchangeable.

Thinking the pathway makes ATP. The PPP produces no ATP. Its products are NADPH and sugar phosphates. Any ATP generated from its carbon skeletons comes later, through glycolysis and oxidative phosphorylation.

Assuming the non-oxidative phase is irreversible. The non-oxidative reactions are reversible. Only the oxidative phase commits carbon.

Forgetting that G6PD is X-linked. This affects inheritance patterns and explains why males are more frequently and more severely affected [4].

Overlooking thiamine. Transketolase needs thiamine pyrophosphate. A patient with thiamine deficiency may have impaired non-oxidative flux even with normal G6PD.

Treating G6PD deficiency as a childhood-only diagnosis. Cases in older adults show that it can remain silent for decades until a trigger appears [8].

Assuming any drug on an avoidance list is proven to cause hemolysis. The evidence is uneven. The quinolone cohort study found a modest and non-significant association [6].

Individual cases require clinical judgment and, where relevant, veterinary or medical consultation. This article describes pathway biology and does not replace professional evaluation.

Quick Review

The PPP runs in the cytosol and produces NADPH and ribose-5-phosphate, not ATP.
The oxidative phase uses G6PD and 6-phosphogluconate dehydrogenase to make two NADPH per glucose-6-phosphate.
The non-oxidative phase uses transketolase and transaldolase to interconvert sugars reversibly.
NADPH fuels reductive biosynthesis and regenerates reduced glutathione.
Ribose-5-phosphate is the backbone for nucleotide synthesis.
G6PD is inhibited by a high NADPH/NADP+ ratio, so the pathway self-regulates.
G6PD deficiency causes hemolysis after oxidative stress such as fava beans or certain drugs.

Carbon Accounting: A Worked Example of One Glucose-6-Phosphate

One of the fastest ways to understand the pentose phosphate pathway is to follow the atoms. Take a single molecule of glucose-6-phosphate and run it through the oxidative phase. The six carbons of the sugar are numbered C1 through C6. In step 1, glucose-6-phosphate dehydrogenase removes hydride from C1 and transfers it to NADP+, forming the first NADPH. The carbon skeleton is now a lactone. In step 2, the lactone ring opens by hydrolysis to give 6-phosphogluconate. In step 3, 6-phosphogluconate dehydrogenase performs an oxidative decarboxylation: C1 leaves as carbon dioxide, a second hydride is transferred to NADP+ to form the second NADPH, and the remaining five-carbon sugar is ribulose-5-phosphate.

So the oxidative phase of one glucose-6-phosphate yields exactly two NADPH, one CO2, and one ribulose-5-phosphate. That is the stoichiometry to memorize, and it is the reason the pathway is described as producing two reducing equivalents per sugar oxidized. The CO2 released here is chemically distinct from the CO2 released by pyruvate dehydrogenase later in aerobic metabolism, and it is not captured by the same regulatory logic.

Now consider what happens when the cell needs NADPH but not ribose. Three molecules of ribulose-5-phosphate enter the non-oxidative phase together. Transketolase and transaldolase rearrange them into two fructose-6-phosphate and one glyceraldehyde-3-phosphate. Those are glycolytic intermediates. Fructose-6-phosphate can be converted back to glucose-6-phosphate by phosphoglucose isomerase, and glyceraldehyde-3-phosphate can be converted to fructose-6-phosphate through the reversible reactions of gluconeogenesis. The net result is that six glucose-6-phosphate molecules can be oxidized to six ribulose-5-phosphate, and the non-oxidative phase can reassemble five of those pentoses into five glucose-6-phosphate molecules, leaving one pentose fully oxidized to CO2. The overall equation for this mode is six glucose-6-phosphate plus twelve NADP+ plus water yielding five glucose-6-phosphate plus six CO2 plus twelve NADPH plus twelve H+. This is the classic recycling stoichiometry, and it explains how a cell can generate large amounts of NADPH without accumulating pentoses it does not need.

The reverse mode is equally instructive. When a cell needs ribose-5-phosphate but wants to conserve NADPH, it can feed glycolytic intermediates into the non-oxidative phase. Fructose-6-phosphate and glyceraldehyde-3-phosphate combine through transketolase and transaldolase to produce ribose-5-phosphate without running G6PD. This is why rapidly dividing cells that already have sufficient reducing power can still make nucleotide precursors. The pathway is not a one-way pipe; it is a reversible carbon distribution network.

Step-by-Step Enzyme Mechanics and Cofactor Chemistry

Understanding the chemistry of each step makes the pathway easier to troubleshoot and easier to remember.

Glucose-6-phosphate dehydrogenase catalyzes a hydride transfer from the C1 hydroxyl of glucose-6-phosphate to the nicotinamide ring of NADP+. The enzyme is highly specific for NADP+ over NAD+, which is a key reason the pathway is functionally separate from glycolysis. The product, 6-phosphogluconolactone, is an unstable internal ester. If 6-phosphogluconolactonase is limiting, the lactone can accumulate and react with proteins, which is one reason cells keep the hydrolysis step efficient.

6-phosphogluconate dehydrogenase is a decarboxylating dehydrogenase. It uses NADP+ again, and the mechanism involves oxidation of the C3 hydroxyl, formation of a beta-keto acid intermediate, and decarboxylation at C1. The enzyme is inhibited by NADPH, reinforcing the redox feedback loop that controls the pathway.

Phosphopentose isomerase converts ribulose-5-phosphate to ribose-5-phosphate through an enediol intermediate. This is an isomerization, not a redox reaction, and it is freely reversible. The enzyme is sometimes called ribose-5-phosphate isomerase, and it is the branch point where the oxidative phase hands off its pentose product to nucleotide synthesis.

Ribulose-5-phosphate epimerase converts ribulose-5-phosphate to xylulose-5-phosphate by inverting the configuration at C3. This creates the second pentose needed for transketolase chemistry. The two pentoses, ribose-5-phosphate and xylulose-5-phosphate, are the substrates that feed the non-oxidative rearrangement.

Transketolase is the most mechanistically interesting enzyme in the pathway. It uses thiamine pyrophosphate to stabilize a carbanion intermediate and transfers a two-carbon ketol unit from a donor ketose to an acceptor aldose. In the first transketolase reaction, xylulose-5-phosphate donates a two-carbon unit to ribose-5-phosphate, yielding glyceraldehyde-3-phosphate and sedoheptulose-7-phosphate. Because TPP is derived from vitamin B1, transketolase activity is a functional readout of thiamine status. In thiamine deficiency, the non-oxidative phase slows, and cells that depend on it for ribose-5-phosphate production may struggle to proliferate or repair.

Transaldolase transfers a three-carbon dihydroxyacetone unit from sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate, producing erythrose-4-phosphate and fructose-6-phosphate. Unlike transketolase, transaldolase does not require TPP. It forms a Schiff base intermediate with a lysine residue in the active site. The enzyme is reversible and helps set the balance of sugar phosphates available for the second transketolase reaction.

The second transketolase reaction transfers a two-carbon unit from another xylulose-5-phosphate to erythrose-4-phosphate, producing fructose-6-phosphate and glyceraldehyde-3-phosphate. After these rearrangements, the carbon from three pentoses has been redistributed into two hexose phosphates and one triose phosphate, all of which are glycolytic intermediates.

Comparing the Pentose Phosphate Pathway with Glycolysis

Students often ask why the cell needs two pathways that start from glucose-6-phosphate. The answer is that they solve different problems.

Glycolysis converts glucose-6-phosphate to pyruvate and generates ATP and NADH. It is catabolic and energy-yielding. The pentose phosphate pathway converts glucose-6-phosphate to NADPH and pentose phosphates. It is anabolic and reducing-power-yielding. Glycolysis is regulated by energy charge, meaning ATP and AMP levels. The PPP is regulated by redox charge, meaning the NADPH/NADP+ ratio.

The two pathways share intermediates. Fructose-6-phosphate and glyceraldehyde-3-phosphate are products of the non-oxidative phase and substrates for glycolysis. This means carbon can flow between the pathways depending on demand. When a cell needs ATP, glycolytic flux increases. When a cell needs NADPH for lipid synthesis or antioxidant defense, oxidative PPP flux increases. When a cell needs ribose for nucleotides, non-oxidative flux can be supplied by glycolytic intermediates.

A useful comparison is the fate of glucose-6-phosphate in a hepatocyte after a carbohydrate-rich meal. Some of it is oxidized by glycolysis to produce ATP. Some is stored as glycogen. Some enters the PPP to provide NADPH for fatty acid synthesis, because the liver is simultaneously converting excess carbohydrate into fat. The PPP and glycolysis are not competing for the same purpose; they are cooperating to meet different metabolic demands.

The Four Modes in Practice: Worked Scenarios

The four metabolic modes described in textbooks become clearer when attached to real cell types.

Adipocytes synthesizing triglycerides need large amounts of NADPH for fatty acid synthase and for the desaturation and elongation reactions. They run the oxidative phase heavily and recycle pentoses through the non-oxidative phase back into glycolytic intermediates. This is mode two: NADPH demand exceeds ribose demand.

Proliferating lymphocytes activated by an immune stimulus need nucleotides for DNA replication. They can feed glucose through glycolysis and divert fructose-6-phosphate and glyceraldehyde-3-phosphate into the non-oxidative phase to make ribose-5-phosphate, while also running the oxidative phase to supply NADPH for reductive biosynthesis and redox defense. This is mode four: both products are needed at high rates.

Red blood cells need NADPH continuously to keep glutathione reduced, but they do not synthesize nucleotides and do not divide. They run the oxidative phase and recycle pentoses back into glycolytic intermediates. This is mode two again, but with an antioxidant rather than biosynthetic purpose.

A resting cell with low biosynthetic demand may need only a small amount of ribose-5-phosphate for RNA turnover. It can supply that ribose through the non-oxidative phase using glycolytic intermediates, sparing NADPH. This is mode three: ribose demand exceeds NADPH demand.

Troubleshooting Pathway Assays and Flux Measurements

Measuring PPP flux is not as simple as measuring G6PD activity, because enzyme activity reports capacity rather than actual flux. Several practical issues arise.

First, sample handling matters. Red blood cells lose G6PD activity over time, and delayed processing can produce falsely low results. Clinical laboratories typically use fresh samples or dried blood spots and follow validated protocols. Neonatal screening programs use fluorescence spot tests or quantitative assays, and abnormal results are confirmed by genetic testing [2]. The choice of screening strategy affects detection yield, and universal versus targeted screening remains an active question [3].

Second, NADPH is unstable and can be oxidized during sample processing. Assays that measure the NADPH/NADP+ ratio must quench metabolism rapidly and protect the sample from light and oxygen. A ratio that drifts during processing will misrepresent the redox state that controls G6PD.

Third, isotopic tracing requires careful choice of label position. Carbon-13 or carbon-14 labeled glucose at C1 versus C6 reveals different information. C1-labeled glucose is released as CO2 in the oxidative phase, so C1 labeling reports oxidative flux. C6-labeled glucose is not released in the oxidative phase, so it reports glycolytic and non-oxidative flux. Comparing the two is a classic way to estimate the proportion of glucose entering the PPP.

Fourth, transketolase activity depends on thiamine status. A low transketolase result may reflect thiamine deficiency rather than a genetic defect in the enzyme itself. This is why transketolase is sometimes used as a functional marker of thiamine status.

Fifth, cancer cell lines often have constitutive PPP upregulation, which can mask regulatory responses. Comparing flux in the presence and absence of a G6PD inhibitor or under oxidative stress can reveal whether the pathway is dynamically regulated or locked in an activated state.

Common Misconceptions Beyond the Basics

Several misconceptions about the pentose phosphate pathway persist even among advanced students.

One is that the pathway is only active in red blood cells. In reality, the PPP operates in essentially all cells. Red blood cells are simply the most dramatic example because they have no alternative NADPH source. Liver, adipose tissue, adrenal cortex, lactating mammary gland, and proliferating cells all run the pathway at high rates.

Another misconception is that NADPH and NADH are functionally interchangeable. They are not. NADPH is used for reductive biosynthesis and antioxidant defense, while NADH is used mainly for ATP production in the electron transport chain. The cell maintains separate pools and separate ratios. Mitochondrial NADPH production via the malic enzyme and isocitrate dehydrogenase is spatially separate from cytosolic PPP NADPH, and the two pools are not fully interchangeable.

A third misconception is that the non-oxidative phase is just a disposal route for excess pentoses. In fact, the non-oxidative phase is the route by which glycolytic intermediates can be converted into ribose-5-phosphate when nucleotide demand is high. It is a biosynthetic pathway in its own right, not merely a cleanup mechanism.

A fourth misconception is that G6PD deficiency always causes symptoms. Many affected individuals are asymptomatic until they encounter an oxidative trigger. A case report of a 70-year-old man shows that the diagnosis can be missed for decades when no trigger has been encountered [8]. This has implications for medication prescribing and for interpreting screening results.

A fifth misconception is that any drug on a G6PD avoidance list is proven to cause hemolysis. The evidence is uneven. A large cohort study found the adjusted odds ratio for hemolysis-related outcomes with quinolones was 1.29 with a confidence interval that crossed 1.0, meaning the evidence for a strong quinolone effect is limited [6]. Dapsone can cause hemolysis and a fall in oxygen saturation even in patients with normal G6PD levels, so the drug itself carries risk independent of genotype [7].

Practical Applications in Research and Medicine

The pentose phosphate pathway is not just a textbook topic. It has direct applications in several fields.

In hematology, G6PD testing is used to diagnose the most common inherited enzyme disorder of red blood cells worldwide, affecting an estimated 500 million people [2]. It is X-linked, so males are affected more often and more severely than females [4]. Testing is indicated before prescribing certain antimalarials, sulfonamides, dapsone, and some quinolones [5][6][7]. Infection, metabolic stress, and surgery can also precipitate hemolysis [1].

In oncology, the PPP is a metabolic vulnerability. Many cancers upregulate G6PD and transketolase to meet NADPH and ribose-5-phosphate demand for rapid proliferation [13]. Chronic stress has been shown to activate an RNMT-ADRB2-MYCBP-PPP axis in esophageal squamous cell carcinoma, increasing expression of G6PD and transketolase and promoting malignant progression [13]. This makes the pathway an attractive target for metabolic inhibitors, though normal tissues also depend on it, so therapeutic windows must be carefully evaluated.

In immunology, the PPP supports the metabolic demands of activated immune cells. A case in a 16-year-old with recurrent perianal abscess and fistula raises the possibility that G6PD dysfunction affects immune defense and epithelial repair beyond the red cell [9]. This suggests that the pathway may have roles in inflammation and tissue repair that are not fully understood.

In surgery and critical care, perfusion and anesthesia teams modify oxygen tension, avoid oxidant drugs such as methylene blue, and minimize mechanical hemolysis in patients with G6PD deficiency [11][12]. Preoperative identification of affected patients can prevent avoidable hemolytic episodes.

In nutrition, thiamine status affects transketolase activity and therefore non-oxidative flux. Severe thiamine deficiency impairs the cell's ability to rebalance sugars and produce ribose-5-phosphate. This is one reason thiamine status matters in conditions with high PPP demand, such as rapid cell proliferation and recovery from oxidative stress.

In asthma research, airway smooth muscle cells show reduced G6PD expression and a low GSH/GSSG ratio, linking the pathway to airway dysfunction [14]. This places the PPP at the intersection of metabolism, redox signaling, and cell fate.

How to Remember the Pathway

A few memory aids help consolidate the steps.

For the oxidative phase, remember the sequence: dehydrogenase, lactonase, dehydrogenase. The first dehydrogenase makes NADPH and a lactone. The lactonase opens the ring. The second dehydrogenase makes NADPH, releases CO2, and leaves a pentose.

For the non-oxidative phase, remember the enzymes in order: epimerase, transketolase, transaldolase, transketolase. The epimerase makes xylulose-5-phosphate. The first transketolase makes glyceraldehyde-3-phosphate and sedoheptulose-7-phosphate. Transaldolase makes erythrose-4-phosphate and fructose-6-phosphate. The second transketolase makes fructose-6-phosphate and glyceraldehyde-3-phosphate.

For the stoichiometry, remember that one glucose-6-phosphate yields two NADPH and one pentose in the oxidative phase, and that three pentoses can be recycled into two hexoses and one triose in the non-oxidative phase.

For the regulation, remember that G6PD is inhibited by NADPH. When the cell has plenty of reducing power, the pathway slows. When NADPH is consumed, the pathway speeds up.

For the clinical relevance, remember that red blood cells have no mitochondria, so the PPP is their only NADPH source. Without it, glutathione cannot be regenerated, peroxide accumulates, and hemolysis follows.

Putting It Together

The pentose phosphate pathway is a cytosolic metabolic network that solves two problems at once: it provides reducing power in the form of NADPH and it provides pentose sugars for nucleotide synthesis. Its oxidative phase is irreversible and committed, while its non-oxidative phase is reversible and flexible. Its regulation is tied to the redox state of the cell rather than to energy charge. Its clinical importance is most visible in G6PD deficiency, where a failure of NADPH production leads to oxidative hemolysis, but its biological reach extends to biosynthesis, antioxidant defense, nucleotide metabolism, cancer progression, immune function, and airway disease. Understanding the steps, the stoichiometry, the modes of operation, and the common misconceptions gives a working researcher or student the tools to interpret experiments, design assays, and reason about metabolic phenotypes in health and disease.

Frequently Asked Questions

What is the pentose phosphate pathway in simple terms?

It is a cytosolic pathway that converts glucose-6-phosphate into NADPH and ribose-5-phosphate. NADPH supports biosynthesis and antioxidant defense, and ribose-5-phosphate builds nucleotides.

Does the pentose phosphate pathway produce ATP?

No. The pathway produces NADPH and phosphorylated sugars. ATP is produced later when its carbon products re-enter glycolysis.

Why do red blood cells depend on the pentose phosphate pathway?

Red blood cells have no mitochondria, so the PPP is their only source of NADPH. Without it, they cannot regenerate reduced glutathione and are vulnerable to oxidative hemolysis.

What triggers hemolysis in G6PD deficiency?

Fava beans, certain antimalarials, sulfonamides, dapsone, some quinolones, infection, and metabolic stress are recognized triggers. Avoiding known triggers prevents recurrent episodes [5][6].

Why does transketolase need thiamine?

Transketolase uses thiamine pyrophosphate as a cofactor to transfer two-carbon units between sugars. Without adequate thiamine, the non-oxidative phase is impaired.

Is the pentose phosphate pathway active in cancer?

Yes. Many cancers upregulate G6PD and other PPP enzymes to meet NADPH and ribose-5-phosphate demand for rapid proliferation [13].